Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21227347 | 0.83 | PTGS1 (0.41) | PTGS1PTGS2TYK2MEN1KMT2A | |
| SCHEMBL20687704 | 0.76 | TYK2 (0.55) | TYK2 | |
| SCHEMBL20689347 | 0.76 | PTGS1 (0.44) | PTGS1PTGS2TYK2MEN1KMT2A | |
| SCHEMBL20687681 | 0.75 | GRM1 (0.49) | PTGS1PTGS2TYK2MEN1KMT2A | |
| SCHEMBL15333550 | 0.75 | PTGS1 (0.47) | PTGS1PTGS2MEN1KMT2AMGLL | |
| SCHEMBL21227430 | 0.74 | TYK2 (0.48) | TYK2 | |
| SCHEMBL20689348 | 0.73 | KMT2A (0.48) | PTGS1PTGS2MEN1KMT2AKDM4E | |
| SCHEMBL20687683 | 0.72 | TYK2 (0.44) | TYK2MEN1KMT2AMGLLALDH1A1 | |
| SCHEMBL20689349 | 0.71 | PTGS1 (0.55) | PTGS1PTGS2MEN1KMT2AMGLL | |
| SCHEMBL20687705 | 0.70 | TYK2 (0.53) | TYK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | PTGS1 4321/4885PTGS2 3848/4885TYK2 1/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | PTGS1 4321/4885PTGS2 3848/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.